Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neurodegenerative

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    102 result(s) found for: Neurodegenerative. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2007-004979-19 Sponsor Protocol Number: EK Reg.-Nr. 040-2007 Start Date*: 2009-01-08
    Sponsor Name:University of Leipzig
    Full Title: In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET)
    Medical condition: To test a diagnostic imaging tool for specifically assessing the nicotinic acetylcholine receptor in vivo in patients with neurodegenerative diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002473-65 Sponsor Protocol Number: PET-PiB Start Date*: 2021-06-16
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: PET-CT study of cerebral regional amyloid burden in Patients with suspected Alzheimer’s disease
    Medical condition: Patients with amnestic or non-amnestic MCI or early dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001955-29 Sponsor Protocol Number: 024PKAN15004 Start Date*: Information not available in EudraCT
    Sponsor Name:Retrophin, Inc.
    Full Title: Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, ...
    Medical condition: Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive,...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) NO (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002343-29 Sponsor Protocol Number: CRCSV2A18 Start Date*: 2020-08-11
    Sponsor Name:Service of Neurology, CHU Liege
    Full Title: Synaptic modifications in subjective cognitive decline. A study using [18F]UCB-H, a synaptic vesicle 2A radiotracer.
    Medical condition: Neurodegenerative Cognitive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10048598 Cognitive disorders LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005024-37 Sponsor Protocol Number: 202100647 Start Date*: 2022-01-24
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease
    Medical condition: - Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001427-79 Sponsor Protocol Number: TIRCON2012V1-EXT Start Date*: 2015-03-27
    Sponsor Name:ApoPharma Inc.
    Full Title: Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)
    Medical condition: Pantothenate kinase-associated neurodegeneration (PKAN)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002769-37 Sponsor Protocol Number: DR190058 Start Date*: 2019-11-13
    Sponsor Name:CHRU DE TOURS
    Full Title: Cerebrovascular reaction to nitrous oxide in Resistant Depression: Pilot study (PROTO-BRAIN)
    Medical condition: Resistant Depression - Nervous Breakdown
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004656-22 Sponsor Protocol Number: IIBSP-THK-2015-77 Start Date*: 2017-10-10
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Pilot study of the [18F]THK-5351 positron emission tomography (PET) tracer in different tauopathies.
    Medical condition: Taupatías
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004439-36 Sponsor Protocol Number: ACP-103-047 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004328-40 Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage Start Date*: 2013-03-01
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES
    Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003536-36 Sponsor Protocol Number: ACP-103-046 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ...
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000094-36 Sponsor Protocol Number: BioFINDER_2 Start Date*: 2017-03-31
    Sponsor Name:Skåne University Hospital
    Full Title: The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders
    Medical condition: Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cogni...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    19.1 10029205 - Nervous system disorders 10012267 Dementia PT
    19.1 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    19.1 10029205 - Nervous system disorders 10028037 Movement disorders (incl parkinsonism) HLGT
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    19.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    19.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    19.1 10029205 - Nervous system disorders 10048598 Cognitive disorders LLT
    19.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.1 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    19.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    19.1 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    19.1 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002027-26 Sponsor Protocol Number: 2405 Start Date*: 2016-04-13
    Sponsor Name:University of Bristol
    Full Title: TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Medical condition: Mild Cognitive Impairment Mild Alzheimer's disease
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-005007-40 Sponsor Protocol Number: S62874 Start Date*: 2020-02-04
    Sponsor Name:University Hospitals Leuven
    Full Title: Natural history study in adult patients with SMA types 2-3-4 and Role of neurodegenerative and neuro-inflammatory biomarkers in SMA adults treated with nusinersen.
    Medical condition: Adult patients with spinal muscular atrophy (SMA) type 2, type 3, or type 4
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002640-23 Sponsor Protocol Number: APHP200003 Start Date*: 2020-12-14
    Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
    Full Title: Effect of increased oxytocin doses on the mode of delivery in obese primiparous women with spontaneous labour. A double-blind, randomised, controlled trial
    Medical condition: To compare the rates of caesarean section in obese patients with spontaneous labour between two oxytocin dosage regimens
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004051-11 Sponsor Protocol Number: 1 Start Date*: 2008-12-18
    Sponsor Name:Oxford Racliffe NHS Trust
    Full Title: Amiloride Treatment in Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004919-55 Sponsor Protocol Number: 04-01-1980 Start Date*: 2007-12-27
    Sponsor Name:Medizinische Universität Innsbruck, Universitätsklinik für Neurologie
    Full Title: Untersuchung der Dosis-Wirk-Beziehung unterschiedlicher Erythropoetin-Dosen auf Frataxin bei Friedreich Ataxie
    Medical condition: Die Friedreich Ataxie ist eine autosomal-rezessiv vererbte, progressive neurodegenerative Erkrankung, die mit einer Inzidenz von rund 1:50.000 auftritt. Es handelt sich dabei um die am häufigsten v...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000460-34 Sponsor Protocol Number: ALCAT Start Date*: 2015-11-18
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)
    Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001200-38 Sponsor Protocol Number: 4C-2011-02 Start Date*: 2012-09-07
    Sponsor Name:BCN Peptides S.A.
    Full Title: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective dru...
    Medical condition: Prevention of neurodegeneration which occurs in Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 15:20:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA